| |
| |
|
| Insider
Information: |
Squinto Stephen P |
| Relationship: |
Director, 10% Owner |
| City: |
Cheshire |
| State: |
CT |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
238,160 |
|
|
Indirect Shares
|
6,290,493 |
|
|
| Direct
Value |
$19,437,710 |
|
|
|
Indirect Value
|
$19,013,945 |
|
|
| Total
Shares |
6,528,653 |
|
|
| Total
Value |
$38,451,655 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alexion Pharmaceuticals Inc |
ALXN |
EVP, Chief Global Ops.... |
2014-10-27 |
106,508 |
2013-10-28 |
104,186 |
Premium* |
|
|
Springworks Therapeutics, Inc. |
SWTX |
Director, 10% Owner |
2022-05-19 |
131,652 |
2022-05-19 |
6,186,307 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
148 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2009-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
33,590 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2009-03-10 |
4 |
S |
$32.34 |
$10,316 |
D/D |
(319) |
33,271 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2009-03-11 |
4 |
GD |
$31.67 |
$62,897 |
D/D |
1,986 |
31,285 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2009-03-16 |
4 |
S |
$34.25 |
$93,057 |
D/D |
(2,717) |
28,568 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2009-07-10 |
4 |
S |
$36.93 |
$11,744 |
D/D |
(318) |
28,250 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2009-07-16 |
4 |
S |
$38.96 |
$12,350 |
D/D |
(317) |
28,251 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2009-08-04 |
4 |
AS |
$45.00 |
$189,000 |
D/D |
(4,200) |
28,251 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2009-08-04 |
4 |
OE |
$32.25 |
$135,450 |
D/D |
4,200 |
32,451 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2010-01-11 |
4 |
S |
$47.67 |
$69,837 |
D/D |
(1,465) |
26,786 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2010-01-19 |
4 |
S |
$47.22 |
$15,677 |
D/D |
(332) |
26,454 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2010-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
35,454 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2010-02-16 |
4 |
OE |
$13.79 |
$220,640 |
D/D |
16,000 |
51,454 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2010-02-16 |
4 |
S |
$46.60 |
$745,600 |
D/D |
(16,000) |
35,454 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2010-07-12 |
4 |
S |
$51.91 |
$12,926 |
D/D |
(249) |
35,205 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2010-07-16 |
4 |
S |
$51.08 |
$16,959 |
D/D |
(332) |
34,873 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2010-09-13 |
4 |
OE |
$10.19 |
$137,346 |
D/D |
12,416 |
39,873 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2010-09-13 |
4 |
S |
$60.89 |
$756,010 |
D/D |
(12,416) |
34,873 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2010-11-03 |
4 |
S |
$70.14 |
$701,400 |
D/D |
(10,000) |
34,873 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2010-11-03 |
4 |
OE |
$10.36 |
$103,600 |
D/D |
10,000 |
44,873 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2011-01-10 |
4 |
S |
$81.27 |
$22,756 |
D/D |
(280) |
34,593 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2011-01-18 |
4 |
OE |
$10.36 |
$496,000 |
D/D |
34,000 |
68,247 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2011-01-18 |
4 |
AS |
$82.66 |
$2,919,280 |
D/D |
(34,346) |
34,247 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2011-01-27 |
4 |
S |
$84.70 |
$112,651 |
D/D |
(1,330) |
32,917 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research and Development |
• – – |
2011-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
7,000 |
39,917 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research and Development |
• – – |
2011-02-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
280 |
39,637 |
0 |
- |
|
148 Records found
|
|
Page 3 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
